Ind-Swift Laboratories FY26 Results: Revenue Grows, Profit Impacted by Base Effect

Ind-Swift Laboratories' standalone revenue for the financial year ended March 31, 2026, reached ₹635.89 crore, marking a 13.11% increase from ₹562.17 crore in FY2025.

Standalone net profit for the same period stood at ₹42.56 crore, a significant decrease of 83.38% from ₹256.09 crore in FY2025.

Reader Takeaway: Amalgamation boosts revenue, but lower profit is due to prior year one-off gains, not core business.

What just happened

Ind-Swift Laboratories has released its financial results for the fiscal year ended March 31, 2026. The company reported an increase in revenue but a substantial drop in net profit compared to the previous fiscal year. This profit decline is mainly due to a high exceptional income recorded in FY2025, which was absent in FY2026. The company also underwent a corporate restructuring through amalgamation and equity conversion via warrants.

Why this matters

For investors, the revenue growth indicates business expansion, potentially from the recent amalgamation. However, the significant drop in net profit requires careful consideration, as it's primarily a base effect from prior year's one-time gains. The unmodified audit opinion provides assurance on financial reporting. The pending asset sale is a minor point to watch for closure.

The backstory

The amalgamation of Ind Swift Limited (ISL) with Ind-Swift Laboratories became effective on August 8, 2025, with shares issued to ISL shareholders on August 25, 2025. During the financial year, 1.95 crore warrants were converted into equity shares, while 65 lakh warrants were forfeited. The previous fiscal year, FY2025, recorded substantial exceptional income of ₹215.88 crore, significantly boosting its net profit. In contrast, FY2026 recorded an exceptional loss of ₹11.01 crore.

What changes now

The amalgamation is now effective, integrating Ind Swift Limited into the company's operations. The conversion of warrants has altered the equity structure. Investors should now focus on the operational performance of the combined entity moving forward.

Risks to watch

The primary watch point is the pending final balance of ₹1.10 crore from the sale of Unit-IV, Baddi land. While not a major financial risk given the overall scale, its completion signifies the finalization of asset disposals.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Standalone Revenue (FY2026): ₹635.89 crore
• Standalone Revenue (FY2025): ₹562.17 crore (+13.11% change)
• Standalone Net Profit (FY2026): ₹42.56 crore
• Standalone Net Profit (FY2025): ₹256.09 crore (-83.38% change)
• FY2025 Exceptional Income: ₹215.88 crore
• FY2026 Exceptional Items: ₹11.01 crore (loss)
• Amalgamation Effective Date: August 8, 2025

What to track next

Investors should monitor the integration progress post-amalgamation and the company's core operational profitability in upcoming quarters. The finalization of the Unit-IV, Baddi land sale should also be tracked for closure.